LOGIN  |  REGISTER
Amneal Pharmaceuticals
Recursion

Avanos Medical to Present at the Stifel 2023 Healthcare Conference

November 07, 2023 | Last Trade: US$11.97 0.01 0.08

ALPHARETTA, Ga., Nov. 7, 2023 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced that Joe Woody, chief executive officer, and Michael Greiner, senior vice president, chief financial officer, and chief transformation officer, will participate in an analyst-led fireside chat at the Stifel 2023 Healthcare Conference on Tuesday, Nov. 14 at approximately 10:20 a.m. ET.

A webcast of the conference presentation will be available on the Investors section of the Avanos Medical website and will be archived on that site.

About Avanos Medical, Inc.

Avanos Medical, Inc. (NYSE: AVNS) is a medical technology company focused on delivering clinically superior medical device solutions that will help patients get back to the things that matter. Headquartered in Alpharetta, Georgia, we are committed to addressing some of today's most important healthcare needs, including providing a vital lifeline for nutrition to patients from hospital to home, and reducing the use of opioids while helping patients move from surgery to recovery. We develop, manufacture and market our recognized brands globally and hold leading market positions in multiple categories across our portfolio. For more information, visit Avanos.com and follow Avanos Medical on Twitter (@AvanosMedical), LinkedIn and Facebook.

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page